Zealand Pharma A/S 8/15/2024 Earnings Report

Zealand Pharma A/S EPS Results

• Actual EPS: -$0.67
• Consensus EPS: -$0.61
• Beat/Miss: Missed by -$0.06
• One Year Ago EPS: N/A

Zealand Pharma A/S Revenue Results

• Actual Revenue: $4.93 million
• Expected Revenue: $0.50 million
• Beat/Miss: Beat by +$4.43 million
• YoY Revenue Growth: N/A

Zealand Pharma A/S Announcement Details

• Date: 8/15/2024
• Time: N/A
• Conference Call Date: N/A
• Conference Call Time: N/A

Zealand Pharma A/S (OTCMKTS:ZLDPF) is a Denmark‐based biopharmaceutical company specializing in the discovery, design and development of peptide‐based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia. The company is also developing glepaglutide, a long‐acting GLP-2 analog for the management of short bowel syndrome, with ongoing clinical trials assessing its ability to reduce parenteral support dependency. Zealand has entered strategic collaborations with leading pharmaceutical firms to co‐develop and commercialize select programs, leveraging global regulatory and commercial expertise to accelerate patient access.

Founded in 1998 and headquartered in Copenhagen, Zealand Pharma conducts research and development activities in Scandinavia while maintaining partnerships and licensing agreements that extend its reach to markets in Europe, North America and Asia. The company’s leadership, including CEO Emmanuel Dulac, brings together expertise in peptide science, clinical development and corporate strategy. Zealand Pharma’s dual listing on the Copenhagen Stock Exchange and OTC markets in the U.S. underscores its commitment to broad investor engagement and global growth.